Gossamer Bio (NASDAQ:GOSS) Rating Lowered to Sell at Wall Street Zen

Gossamer Bio (NASDAQ:GOSS) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Gossamer Bio in a research note on Thursday, September 11th. Wedbush boosted their target price on Gossamer Bio from $4.00 to $5.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 6th. Finally, Scotiabank assumed coverage on Gossamer Bio in a research note on Monday, July 14th. They set a “sector outperform” rating and a $11.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Gossamer Bio presently has a consensus rating of “Buy” and a consensus target price of $8.50.

Gossamer Bio Price Performance

GOSS stock opened at $3.16 on Friday. The business has a 50 day moving average price of $2.29 and a 200 day moving average price of $1.54. The stock has a market cap of $718.52 million, a price-to-earnings ratio of -5.10 and a beta of 1.95. Gossamer Bio has a fifty-two week low of $0.66 and a fifty-two week high of $3.60. The company has a quick ratio of 4.40, a current ratio of 4.40 and a debt-to-equity ratio of 6.70.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. The firm had revenue of $11.49 million during the quarter, compared to analysts’ expectations of $4.12 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 344.81%. Equities research analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in Gossamer Bio during the second quarter worth $26,000. Banco BTG Pactual S.A. acquired a new position in Gossamer Bio during the second quarter worth $27,000. Drive Wealth Management LLC grew its holdings in Gossamer Bio by 52.7% during the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock worth $31,000 after acquiring an additional 8,797 shares during the period. Virtu Financial LLC acquired a new position in Gossamer Bio during the first quarter worth $38,000. Finally, ProShare Advisors LLC acquired a new position in Gossamer Bio during the second quarter worth $48,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.